Clinical Trial

Baricitinib for Post-HSCT Persistent Thrombocytopenia

Name: Baricitinib for Post-HSCT Persistent Thrombocytopenia — clinical trial record (NCT07535645)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BAPT

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a prospective, open-label phase 1b/2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation.

Trial Details

NCT Number	NCT07535645
Lead Sponsor	Peking University People's Hospital
Conditions	Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment	28 participants
Start Date	2026-04-15
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-09-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-17